We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Articles

Results 1 to 5 of 5
Most popular |Most recent


LawFlash: Updated Guidance from DOJ Puts Effectiveness at Center of Corporate Compliance Programs

USA - May 2 2019 In its updated guidance issued on Tuesday, the US Department of Justice Criminal Division places effectiveness at the epicenter of its factors to be...

John J. Pease, III, Jonelle C. Saunders, Amanda B. Robinson.

DOJ: Corporate Compliance Programs Must Be Truly Effective

USA - May 1 2019 In its updated guidance issued on Tuesday, the US Department of Justice Criminal Division places effectiveness at the epicenter of its factors to be...

John J. Pease, III, Jonelle C. Saunders, Amanda B. Robinson.

DOJ Assistant AG Benczkowski Reinforces Value of Transparency in Fraud, Corruption Actions

USA - March 11 2019 In recent remarks, AAG Brian A. Benczkowski emphasized that the US Department of Justice remains serious about fighting corporate fraud and...

David I. Miller, Michaela Dragalin Young, Eric W. Sitarchuk, Martha B. Stolley.

FDA and Amarin Reach Settlement on First Amendment and Off-Label Statements

USA - March 10 2016 On March 8, the US District Court for the Southern District of New York approved settlement terms in connection with Amarin Pharma, Inc., et al. v. U...

Kathleen M. Sanzo, Jacqueline R. Berman.

Practical implications from Amarin

USA - August 10 2015 Amarin is an important US district court opinion affirming the importance of the Second Circuit's Caronia decision and finding that pharmaceutical...

Margaret Erin Rodgers Schmidt, Kathleen M. Sanzo, Alison Tanchyk, Eric W. Sitarchuk, John S. Rah.